Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 47.37 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $32.000 thousand which missed the analyst consensus estimate of $300.000 thousand by 89.33 percent. This is a 98.62 percent decrease over sales of $2.318 million the same period last year.